On August 1st, the INC Research/inVentiv Health merger became a reality. The closing of this deal marked the coming together of two great businesses and, more importantly, the beginning of an industry-changing new company. A company with comprehensive resources, global scale and a unique approach to bringing new therapies to market based on the technologies, data, science and knowledge of today - instead of the practices of the past decades.
While it is just beginning, our new company is already generating excitement and anticipation…
“The new organization’s combined clinical scale, therapeutic depth and expertise will allow it to partner with biopharmaceutical companies of all sizes to navigate an increasingly complex biopharmaceutical development and commercialization environment…” - The Deal
“We believe INCR’s deep therapeutic expertise combined with inVentiv’s FSP and CCO capabilities should provide a compelling solution in a market that continues to see significant benefits to scale…” - J.P. Morgan
“… this merger should be a plus for small Biotech to have additional commercial options.” - Customer
A dedicated team of individuals from INC Research/inVentiv Health will work together to build and shape the only fully integrated, end-to-end Contract Research and Contract Commercial Organization. A new business that will address new market realities through clinical and commercial sharing expertise, data and insights to meet the needs of global biopharmaceutical firms large and small. One company, purpose-built to achieve a goal the industry has been seeking for a long time: Biopharmaceutical Acceleration.
Because nothing like it has ever existed before, the company will have a new name. A new look and feel. A new identity. It will incorporate the best practices and processes of INC Research and inVentiv Health to shape a company that is a far better fit for the modern biopharmaceutical world. And it will have a singular purpose...Shortening the distance from lab to life.™
Coming January 2018. The countdown begins today.
For more information or questions related to the merger, please contact the individuals below:
Investor Relations Contact:
Vice President, Investor Relations
+1 919 745 2745
Senior Director, External Communications
+1 202 210 5992